Work

Add dupilumab and mepolizumab to the toolbox for patients with chronic obstructive pulmonary disease and type 2 inflammation

Year: 2026

Type: article

Abstract: Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide. A subset of patients with COPD have pulmonary type 2 inflammation, creating an opportunity for a personalised medicine approach in these individuals. Dupilumab and mepolizumab are approved for the management of COPD with type 2 inflammation, while ensifentrine is approved for use in a broader COPD population. Several more biological therapies (including tezepemulab, tozorakimab and itepekimab) remain under investigation for COPD with type 2 inflammation.

Source: Drugs & Therapy Perspectives

DOI: 10.1007/s40267-026-01231-2

Authors: Thomas B. Burgess, Connie Kang

Institution: Springer Nature (New Zealand)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,490